The Comparision of Effectiveness Between Vernonia Cinerea (L) Less and bupropion Smoking Cessation
Keywords:
smoking cessation, bupropion, VernoniaCinerea (L) LessAbstract
This study aimed to compare effectiveness between Vernonia Cinerea (L) and bupropion for smoking cessation as well as to study adverse events of Vernonia Cinerea.
Methodology: The randomized double blind controlled trial with
two-parallel groups was conducted in Princess Mother National Institute on Drug Abuse Treatment during 2008-2010. The 89 smokers from private companies, government sectors and state enterprises were voluntarily enrolled. Of these, 45 smokers were in Vernonia Cinerea group while the rest were in bupropion group. The participants in Vernonia Cinerea group were given 4 gm tea bag three times a day and bupropion identical placebo 1 tablet daily after meal on the first 3 days and followed by 4 gm tea bag three times a day and 1 placebo tablet 2 times a day to complete 7 weeks. The participants in bupropion group were given bupropion 150 mg daily after meal on the first 3 days and followed by 1 tablet 2 times a day to complete 7 weeks and Vernonia Cinerea tea bag identical placebo three times a day. The target quit date was the eighth day of treatment. Education and counseling about smoking cessation by doctors, pharmacists and nurses were delivered to participants in both groups at week 0, 2, 4 and 7. Tobacco abstinence was followed up every month and evaluated by participants themselves and urine nicotine.
Results: The participants were 35.84 + 7.85years of age and smoked 14.74 + 6.60 tobacco/day. Of all participants, 52.8% had smoked for 10-20 years with Fagerstom test for nicotine dependence of 4.67 + 2.41.Physical and laboratory examinations before and after treatment were within normal limit in both groups. The abstinence rate continued after treatment at week 7 were 15.6% in Vernonia Cinerea group and 25% in bupropion group (p=0.267). At week 16, there were 11.11% in Vernonia Cinerea group and 11.4% in bupropion group (p=0.778). At the end of treatment in week 24, there were 11.11% in Vernonia Cinerea group and 6.8% in bupropion group (p=0.308). The most common adverse events of Vernonia Cinereawere vertigo/headache (53.3%) followed by tingling tongue (28.9%) and dry throat (26.7%). Similarly, they were vertigo/ headache (50%) followed by insomnia (31.8%) and dry throat (26.7%) in bupropion group.
Conclusion: Vernonia Cinerea tea showed the similar effectiveness with bupropion. During 7 weeks of treatment, there was no serious adverse event among patients in Vernonia Cinerea group.
References
2. U.S. Department of Health and Human Services. Treatment tobacco use and dependence: A clinical practice guideline (AHRQ Publication No. 00-0032)
3. Saenghirunvattana, S. Smoking cessation. Rama Med J 1991;22(1):4-10.
4. ฝ่ายเภสัชกรรม โรงพยาบาลศิริราช. คู่มือบัญชียาหลัก โรงพยาบาลศิริราช (อัดสำเนา). กรุงเทพมหานคร. ฝ่ายเภสัชกรรม โรงพยาบาลศิริราช; 2548.
5. นริศรา ยิ้มแย้ม. หญ้าดอกขาวอีกทางเลือกหนึ่งของผู้ที่ต้องการเลิกบุหรี่. จุลสารบุหรี่และสุขภาพ 2541;8(1):15-6.
6. Dhar ML, Dhar D, DhawanBN, Mehrotra BN, Ray C. Screening of indian plants for biological activity: Part 1. Indian J Exp Bio 1968;6:232-47.
7. Muir CK. Depressant action of an extract of Vernonia cinerea. Med J Malasia 1981;36:119-21.
8. Pendse, A.K., Ghosh R, Goyal A, Singh PP. Effect of indigenous drugs on idiopathi chyperoxaluria in stone formers. Asian Medical Journal 1984;2:136-9.
9. Marya SK, Singla S. Role of Cystone in management of Ureteric Calculi. Medicine and Surgery 1993;December:21-4.
10. ฉวีวรรณ ดวงจร และคณะ. การเปรียบเทียบประสิทธิผลของยาสมุนไพรหญ้าดอกขาวกับยาหลอกในการลดการสูบบุหรี่. ในกลุ่มงานวิจัยทางคลินิกด้านการแพทย์แผนไทยและสมุนไพร สถาบันการแพทย์แผนไทย. รวมบทคัดย่องานวิจัยด้านการแพทย์แผนไทยและสมุนไพร; 2550.
11. ศักดิ์วิชา ไซสวัสดิ์, มนัชยา มรรคอนันตโชติ. การศึกษารูปแบบการบำบัดผู้ติดบุหรี่ด้วยการใช้หญ้า ดอกขาวและธรรมชาติบำบัด ของโรงพยาบาลเทิง จังหวัดเชียงราย. นนทบุรี: สถาบันควบคุมการ บริโภคยาสูบ กระทรวงสาธารณสุข; 2539.
12. ปรีดา เบญจนากาศกุล. ประสิทธิผลของหญ้าดอกขาวในการเลิกบุหรี่. วิทยานิพนธ์ปริญญาเภสัช
ศาสตรมหาบัณฑิต : บัณฑิตวิทยาลัย จุฬาลงกรณ์มหาวิทยาลัย; 2549.
13. Paeratakul O. Chemical Constituents, Biological Activity of Vernoniacinerea (L.) Less., and its Formulation Development as a Smoking Cessation Aid. Journal of Thai Traditional & Alternative Medicine 2010;8(1):81-92.
14. บัญชียาหลักแห่งชาติฉบับที่ 4 พ.ศ. 2554. บัญชียาจากสมุนไพร. สืบค้นจาก
www.dms.moph.go.th/dmsweb/main_page/herbal_book.pdf.
15. สุนันทา สุขสุมิตร. สมุนไพรหญ้าดอกขาว. Available from: http://www.thaihealth.or.th/ healthcontent/article/18857.
16. Leelarungrayub D, Pratanaphon S, PothongsununP, Sriboonreung T, Yankai A, Bloomer RJ. Vernoniacinerea Less.supplementation and strenuous exercise reduce smoke rate: relation to oxidative stress status and beta-endophin release in active smokers. J Int Soc Sports Nutr 2010 May 26;7:21.
17. Crain S, Crain MA, Crain SM. Emotional and Physical Distress Relief Using a Novel
Endorphinergic Formulation. JBBS 2013;3(6):441-53.
18. Supakit Wongwiwatthananukit, Preeda Bebjanakaskul, Thanapat Songsak, Somporn Suwanmajo and Viroj Verachai. EFFICACY OF VERNONIA CINEREA FOR SMOKING CESSATION. J Health Res 2009;23(1):31-36.
19. Wilkes S. The use of bupropion SR in cigarette smoking cessation.International journal of chronic obstructive pulmonary disease 2008;3(1):45-53.
20. Tombor I, Shahab L, Brown J, West R. Positive smoker identity as a barrier to quitting smoking: Findings from a national survey of smokers in England. Drug Alcohol Depend 2013;133(2):740-745.
21. Kekade, S.R. Cystone Therapy in urolithiasis. Probe 1985; 24(3):167-8.
